Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases
- PMID: 15469396
- DOI: 10.1517/14728222.8.5.473
Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases
Abstract
The need to pharmacologically control the proteolytic activity of matrix metalloproteinases (MMPs) has been commonly acknowledged, despite its limited efficacy in clinical trials. Among the reasons that explain this failure is our limited understanding of the signals that control the expression of MMPs in different cell types during different pathological conditions. Thus, future therapies must rely on more selective approaches. With the continually increasing body of proof implicating MMPs in a large number of diseases, it has become a priority to establish the pertinence of molecules involved in the signalling pathways leading to the expression of these enzymes. MMP-9 is a case in point: its dramatic overexpression in cancer and various inflammatory conditions clearly points to the molecular mechanisms controlling its expression as a potential target for eventual rational therapeutic intervention. In this article, recent progress in the signalling pathways that regulate MMP-9 expression is reviewed, and the latest strategies to be considered in the search for a specific inhibitor of its expression are presented.
Similar articles
-
Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases.J Immunol. 2003 Jun 15;170(12):6244-9. doi: 10.4049/jimmunol.170.12.6244. J Immunol. 2003. PMID: 12794156
-
Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways.J Immunol. 2000 Nov 15;165(10):5788-97. doi: 10.4049/jimmunol.165.10.5788. J Immunol. 2000. PMID: 11067938
-
Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells.J Immunol. 2004 Dec 1;173(11):6973-80. doi: 10.4049/jimmunol.173.11.6973. J Immunol. 2004. PMID: 15557194
-
Matrix metalloproteinases as therapeutic targets in cancer.Curr Cancer Drug Targets. 2005 May;5(3):203-20. doi: 10.2174/1568009053765799. Curr Cancer Drug Targets. 2005. PMID: 15892620 Review.
-
Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer.Curr Drug Targets. 2000 Sep;1(2):163-83. doi: 10.2174/1389450003349317. Curr Drug Targets. 2000. PMID: 11465069 Review.
Cited by
-
TWEAK and the central nervous system.Mol Neurobiol. 2007 Jun;35(3):255-65. doi: 10.1007/s12035-007-0024-z. Mol Neurobiol. 2007. PMID: 17917114 Review.
-
CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.BMC Cancer. 2018 Apr 10;18(1):400. doi: 10.1186/s12885-018-4317-6. BMC Cancer. 2018. PMID: 29631554 Free PMC article.
-
Functional Roles of N-Linked Glycosylation of Human Matrix Metalloproteinase 9.Traffic. 2015 Oct;16(10):1108-26. doi: 10.1111/tra.12312. Epub 2015 Sep 2. Traffic. 2015. PMID: 26207422 Free PMC article.
-
MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma.Tumour Biol. 2014 Dec;35(12):12567-73. doi: 10.1007/s13277-014-2577-6. Epub 2014 Sep 19. Tumour Biol. 2014. PMID: 25234715
-
Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias.Cancers (Basel). 2014 Apr 4;6(2):796-812. doi: 10.3390/cancers6020796. Cancers (Basel). 2014. PMID: 24713998 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
